Literature DB >> 8651147

Psychiatric comorbidity: prevalence in methadone maintenance treatment.

J B Milby1, M K Sims, S Khuder, J E Schumacher, N Huggins, A T McLellan, G Woody, N Haas.   

Abstract

This study examines prevalence rates for DSM-III-R anxiety and affective disorders in three follow-up samples of opioid addicts who were treated with methadone maintenance. At least one anxiety disorder was diagnosed in 55% of the total sample. Affective disorders were found in 58%. At least one anxiety disorder coexisted with at least one affective disorder in 36% of the sample. The research demonstrates that opiate addiction in this sample is most often associated with other comorbid psychopathology. It suggests a need for thorough assessment for general psychopathology in opioid addicts entering addiction treatment, especially assessment for anxiety and affective disorders. It also suggests the need for treatment that focuses on diagnosed mental disorders in addition to drug counseling for the substance abuse disorder.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8651147     DOI: 10.3109/00952999609001647

Source DB:  PubMed          Journal:  Am J Drug Alcohol Abuse        ISSN: 0095-2990            Impact factor:   3.829


  19 in total

1.  Exploring relations among traumatic, posttraumatic, and physical pain experiences in methadone-maintained patients.

Authors:  Declan T Barry; Mark Beitel; Christopher J Cutter; Brian Garnet; Dipa Joshi; Andrew Rosenblum; Richard S Schottenfeld
Journal:  J Pain       Date:  2010-06-20       Impact factor: 5.820

2.  Reasons for Benzodiazepine Use Among Persons Seeking Opioid Detoxification.

Authors:  Michael D Stein; Mitika Kanabar; Bradley J Anderson; Anna Lembke; Genie L Bailey
Journal:  J Subst Abuse Treat       Date:  2016-06-16

3.  Psychiatric and substance use disorders among methadone maintenance patients with chronic hepatitis C infection: effects on eligibility for hepatitis C treatment.

Authors:  Steven L Batki; Kelly M Canfield; Robert Ploutz-Snyder
Journal:  Am J Addict       Date:  2011-05-31

4.  Pain and emotional distress among substance-use patients beginning treatment relative to a representative comparison group.

Authors:  Katharina L Wiest; Jason B Colditz; Kathryn Carr; Victoria J Asphaug; Dennis McCarty; Paul A Pilkonis
Journal:  J Addict Med       Date:  2014 Nov-Dec       Impact factor: 3.702

5.  Chronic pain and opioid abuse: Factors associated with health-related quality of life.

Authors:  Jermaine D Jones; Jonathan S Vogelman; Rachel Luba; Mudassir Mumtaz; Sandra D Comer
Journal:  Am J Addict       Date:  2017-11-21

6.  A developmental model of addictions: integrating neurobiological and psychodynamic theories through the lens of attachment.

Authors:  Mauricio Alvarez-Monjaras; Linda C Mayes; Marc N Potenza; Helena Jv Rutherford
Journal:  Attach Hum Dev       Date:  2018-07-18

7.  Does maternal reflective functioning mediate associations between representations of caregiving with maternal sensitivity in a high-risk sample?

Authors:  Mauricio Alvarez-Monjarás; Thomas J McMahon; Nancy E Suchman
Journal:  Psychoanal Psychol       Date:  2017-10-26

8.  Probabilistic reward- and punishment-based learning in opioid addiction: Experimental and computational data.

Authors:  Catherine E Myers; Jony Sheynin; Tarryn Balsdon; Andre Luzardo; Kevin D Beck; Lee Hogarth; Paul Haber; Ahmed A Moustafa
Journal:  Behav Brain Res       Date:  2015-09-14       Impact factor: 3.332

9.  Subtyping patients with heroin addiction at treatment entry: factor derived from the Self-Report Symptom Inventory (SCL-90).

Authors:  Icro Maremmani; Pier Paolo Pani; Matteo Pacini; Jacopo V Bizzarri; Emanuela Trogu; Angelo Gi Maremmani; Gilberto Gerra; Giulio Perugi; Liliana Dell'Osso
Journal:  Ann Gen Psychiatry       Date:  2010-04-13       Impact factor: 3.455

10.  Are opioid dependence and methadone maintenance treatment (MMT) documented in the medical record? A patient safety issue.

Authors:  Alexander Y Walley; Danielle Farrar; Debbie M Cheng; Daniel P Alford; Jeffrey H Samet
Journal:  J Gen Intern Med       Date:  2009-07-04       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.